logo
Plus   Neg
Share
Email

NiSource Reaffirms FY19 Adj. EPS Outlook - Quick Facts

While reporting financial results for the first quarter, electric utility NiSource Inc. (NI) said Wednesday it is well-positioned to deliver on our commitments for 2019 and continues to project adjusted net operating earnings for fiscal 2019 in the range of $1.27 to $1.33 per share.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $1.31 per share for the year. Analysts' estimates typically exclude special items.

Further, the company expects to make 2019 capital investments of $1.6 to $1.7 billion and grow its net operating earnings per share and dividend by 5 to 7 percent each year through 2022. It also expects to make capital investments of $1.6 to $2.0 billion annually from 2020 through 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Deutsche Post DHL Group were gaining around 5 percent in the morning trading in Germany after the package delivery and supply chain management company reported Tuesday significantly higher profit in its third quarter. Looking ahead, the company anticipates a traditionally strong holiday season in the fourth quarter. The company also confirmed its annual earnings outlook. A New York regulator has launched an investigation into the credit card practices of Goldman Sachs Group Inc. for alleged gender discrimination in determining limits for Apple's new credit card, which is administered by Goldman Sachs. The Apple Card, Apple's first credit card, was introduced by the tech giant in March this year in partnership with Goldman Sachs and Mastercard. The U.S. Food and Drug Administration approved the first therapy for patients with a rare inherited blood disorder called beta thalassemia. Celegene's Reblozyl is also the first and only FDA-approved erythroid maturation agent, a new class of therapy for such patients. The regulator approved Reblozyl for treating anemia in adult patients with beta thalassemia who require regular RBC transfusions.
Follow RTT
>